Literature DB >> 1313450

Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells.

E Koren1, M W Reichlin, M Koscec, R D Fugate, M Reichlin.   

Abstract

Autoantibodies to ribosomal P-proteins are present in 12-16% of patients with systemic lupus erythematosus and are associated with neuropsychiatric disease. As the ribosomal P proteins are located in the cytoplasm, the pathogenic effects of their cognate autoantibodies are unclear. In this study affinity-purified anti-P autoantibodies were used to explore the cell surface of several types of human and animal cells. Immunofluorescence as well as EM immunogold analysis demonstrated, on the surface of human hepatoma cells, the presence of an epitope that is antigenically related to the immunodominant carboxy terminus of P-proteins. The presence of this epitope was also demonstrated on the surface of human neuroblastoma cells and, to a lesser extent, on human fibroblasts. Furthermore, the Western blot technique revealed in purified human and animal plasma membranes a 38-kD protein that is closely related or identical with ribosomal P0 protein. The availability of reactive P peptide on the surface of cells makes possible the direct effect of autoantibodies on the function and viability of cells that express this antigenic target. This delineates one of the possible impacts of anti-P antibodies in disease expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313450      PMCID: PMC442983          DOI: 10.1172/JCI115707

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  UV-induced DNA excision repair in rat fibroblasts during immortalization and terminal differentiation in vitro.

Authors:  J Vijg; E Mullaart; F Berends; P H Lohman; D L Knook
Journal:  Exp Cell Res       Date:  1986-12       Impact factor: 3.905

2.  Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus.

Authors:  K Elkon; S Skelly; A Parnassa; W Moller; W Danho; H Weissbach; N Brot
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Use of glutaraldehyde as a coupling agent for proteins and peptides.

Authors:  M Reichlin
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

4.  Clinical and serologic associations of the antiribosomal P protein antibody.

Authors:  E Bonfa; K B Elkon
Journal:  Arthritis Rheum       Date:  1986-08

5.  Separation of large denatured peptides by reverse phase high performance liquid chromatography. Trifluoroacetic acid as a peptide solvent.

Authors:  W C Mahoney; M A Hermodson
Journal:  J Biol Chem       Date:  1980-12-10       Impact factor: 5.157

6.  Association between lupus psychosis and anti-ribosomal P protein antibodies.

Authors:  E Bonfa; S J Golombek; L D Kaufman; S Skelly; H Weissbach; N Brot; K B Elkon
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

7.  Monoclonal antibodies against eucaryotic ribosomes. Use to characterize a ribosomal protein not previously identified and antigenically related to the acidic phosphoproteins P1/P2.

Authors:  H Towbin; H P Ramjoué; H Kuster; D Liverani; J Gordon
Journal:  J Biol Chem       Date:  1982-11-10       Impact factor: 5.157

8.  The number of copies of ribosome-bound proteins L7 and L12 required for protein synthesis activity.

Authors:  C C Lee; C R Cantor; B Wittmann-Liebold
Journal:  J Biol Chem       Date:  1981-01-10       Impact factor: 5.157

9.  Characterization of the asialoglycoprotein receptor in a continuous hepatoma line.

Authors:  A L Schwartz; S E Fridovich; B B Knowles; H F Lodish
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

10.  DNA receptor dysfunction in systemic lupus erythematosus and kindred disorders. Induction by anti-DNA antibodies, antihistone antibodies, and antireceptor antibodies.

Authors:  R M Bennett; B L Kotzin; M J Merritt
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  39 in total

Review 1.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 2.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults.

Authors:  Z J Pan; C J Anderson; H A Stafford
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

Review 4.  Anti-ribosomal P antibodies and lupus nephritis.

Authors:  Shunsei Hirohata
Journal:  Clin Exp Nephrol       Date:  2011-06-07       Impact factor: 2.801

5.  Antibodies to ribosomal P proteins and hepatic damage in undifferentiated CTD.

Authors:  J C Torre; L Mozo; A Suárez; E Ramos; C Gutiérrez
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 6.  Anti-lymphocyte autoantibodies in systemic lupus erythematosus.

Authors:  J B Winfield; P D Fernsten; J K Czyzyk
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

7.  Passive transfer of antibodies to the linear epitope 60 kD Ro 273-289 induces features of Sjögren's syndrome in naive mice.

Authors:  J S Maier-Moore; B T Kurien; A D'Souza; L Bockus; S Asfa; Y Dorri; S Hubbell; O Yeliosof; D Obeso; T R Schoeb; R Jonsson; R H Scofield
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 8.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

9.  Anti-dsDNA antibodies cross-react with ribosomal P proteins expressed on the surface of glomerular mesangial cells to exert a cytostatic effect.

Authors:  K H Sun; W T Liu; C Y Tsai; S J Tang; S H Han; C L Yu
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

10.  The P domain of the P0 protein of Plasmodium falciparum protects against challenge with malaria parasites.

Authors:  K Rajeshwari; Kalpesh Patel; Savithri Nambeesan; Monika Mehta; Alfica Sehgal; Tirtha Chakraborty; Shobhona Sharma
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.